Overview

A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Status:
Completed

Trial end date:
2011-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate of the study of different CNTO 328 doses and schedules and to see if CNTO 328 has any effect on Non-hodgkin's Lymphoma, Multiple Myeloma or Castleman's disease.

Phase:

Phase 1

Details

Lead Sponsor:

Centocor, Inc.

Treatments:

Antibodies, Monoclonal
Siltuximab